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TDC placement Secondary proceduresPredictor OR P OR PArteriovenous graft 0.845 .006 1.403 <.001
Age (per decade) 0.949 .020 1.057 .014
White race 0.864 .012 0.731 <.001
Male gender 0.0831 .001 0.945 .298
BMI (per 5 units) 1.046 .015 1.06 .002BMI, Body mass index; OR, odds ratio.
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Objectives: The Agency for Healthcare Research and
Quality (AHRQ) Inpatient Quality Indicator (IQI) #11,
abdominal aortic aneurysm (AAA) repair inpatient mortal-
ity rate, is a measure of hospital quality, which is publically
reported but has not been externally validated. Because the
measure includes both intact and ruptured aneurysms and
open and endovascular repair, we hypothesized that IQI
#11 does not provide accurate assessment of mortality
risk after AAA repair.
Methods: Using AHRQ IQI software version 4.2, we
calculated observed (O) and expected (E) mortality rates
for IQI #11 for all hospitals performing AAA repair in
the Nationwide Inpatient Sample 2007-2011. We assessed
the correlation between expected rates as determined by
IQI #11 risk-adjustment methodology and observed rates
for all AAA repairs and in four cohorts stratiﬁed by aneu-
rysm stability (ruptured vs intact) and method of repair
(open vs endovascular).
Results: Among 187,773 AAA repairs performed at
1,268 United States hospitals, hospitals’ IQI #11 expected
rates correlated poorly with their observed rates (E: 5.0%6
4.4% vs O: 6.0% 6 9.8%; r ¼ 0.49). For ruptured AAA,
IQI #11 methodology underestimated the mortality risk
of open repair (E: 34% 6 7.2% vs 0: 40.1% 6 38.2%; r ¼
0.20) and endovascular repair (E: 24.8% 6 9% vs 0:
27.3% 6 37.9%; r ¼ 0.08). For intact AAA repair, IQI #11
methodology underestimated the mortality risk of open
repair (E: 4.3% 6 2.4% vs O: 6.3% 6 16.1%; r ¼ 0.24)but overestimated the mortality risk of endovascular repair
(E: 1.3% 6 0.8% vs O: 1.1% 6 3.7%; r ¼ 0.25). Hospitals’
observed mortality rates after intact AAA repair were not
correlated with their mortality rates after ruptured AAA
repair (r ¼ 0.03).
Conclusions: IQI #11 fails to provide an accurate
assessment of inpatient mortality risk after AAA repair.
Our results suggest that due to its poor validity, it is prema-
ture to use IQI #11 for quality reporting. Separate quality
measures that assess mortality risk after repair of ruptured
and intact AAAs, stratiﬁed by the use of open or endovas-
cular repair, should be developed.
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Objectives: The goal of carotid endarterectomy
(CEA) and carotid stenting (CAS) is to limit future stroke
during a patient’s lifetime. We linked data from the
Vascular Quality Initiative (VQI) with Medicare claims to
compare long-term stroke rate and 5-year stroke-free sur-
vival after CEA and CAS.
Methods: We linked 6,188 unique patients who
underwent primary CEA or CAS in VQI (2005-
2011) to their Medicare claims. We used VQI for peri-
operative and 1-year data and added long-term follow-
up from Medicare for stroke or death. We compared
the 5-year freedom from stroke and stroke or death
in crude and inverse propensity-weighted (IPW)
cohorts.
Results: Patients selected for CEA (n ¼ 5,792) or
CAS (n ¼ 396) were similar in age (73 years), and 56%
were asymptomatic in both groups. However, patients
selected for CAS were more likely to have diabetes, cor-
onary disease, congestive heart failure, and renal insufﬁ-
ciency. In-hospital stroke rate was similar for CEA and
CAS, in asymptomatic (1.5% vs 2.2%, P ¼ .34) and symp-
tomatic (2.3% vs 3.5%, P ¼ .29) patients. However, the
incidence of any stroke at 3 years was signiﬁcantly higher
after CAS compared with CEA (23% vs 13%, log-rank
P < .001; Fig). Further, failure to achieve 5-year
stroke-free survival was worse for CAS patients, both
asymptomatic (adjusted hazard ratio, 1.9; 95% conﬁ-
dence interval, 1.5-2.6; P < .001) and symptomatic
(adjusted hazard ratio, 1.6; 95% conﬁdence interval,
1.3-2.0; P < .001).
Conclusions: Patients selected for CAS in VQI have
worse long-term stroke rate and stroke-free survival
compared with patients treated with CEA, even when
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Objectives: We assessed the effects of thoracic endo-
vascular aortic repair (TEVAR) rehearsal with an endovas-
cular surgical simulator in surgical trainees at different
levels in training.
Methods: Twelve trainees in three cohorts (student,
postgraduate year [PGY]1-3, and PGY 4-7) were oriented
to using the Simbionix AngioMentor simulator over four
sessions. Likert scale qualitative analysis evaluated partici-
pant proﬁciency. Analysis of data included one-way analysis
of variance and paired t-tests.
Results: All groups had reduction of total procedure
time (mean 537 6 148 seconds vs 269 6 66 seconds, ﬁrst
session vs fourth; conﬁdence interval [CI], 195-341 seconds;
P < .05) and ﬂuoroscopy time (201 6 74 vs 110 6 37 sec-
onds; CI, 51-132 seconds; P < .05) with case progression.
Procedure time signiﬁcantly decreased in students (551 6
84 vs 313 6 65 seconds; CI 189-287 seconds; P < .05)
and PGY 1-3 (591 6 149 vs 264 6 29 seconds; CI, 113-
541 seconds;P< .02) had a signiﬁcant decrease in procedure
time. Fluoroscopy times were brief overall between individ-
uals and groups and did not change signiﬁcantly with case
progression. Participants acquired proﬁciency after a few
runs in almost every step of the procedure. Endograft sizing
appeared to be the most challenging task by qualitative anal-
ysis. PGY 4-7 trainees had higher technical scores, but this
was not statistically signiﬁcant.
Conclusions: Practice on endovascular surgical simula-
tors can reduce overall procedure and ﬂuoroscopy time,independent of trainee skill level or experience. Endovascu-
lar simulators can be effective tools in residency training and
maintenance of proﬁciency. Further studies are needed to
compare simulator performance with outcomes in real cases.
Fig. Comparison among groups in TEVAR total procedure time.Author Disclosures: A. F. Gosling: Nothing to disclose;
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Objectives: To evaluate the long-term (up to 24
months) outcome of stenting in TASC A and B and
TASC C and D iliac lesions in a controlled setting.
Methods: The BRAVISSIMO study is a prospective,
nonrandomized, multicenter, multinational, monitored
trial including 325 patients with aortoiliac lesions. The
end point is the primary patency at 24 months, deﬁned
as a target lesion without a hemodynamically signiﬁcant
stenosis on duplex ultrasound imaging (>50%, systolic ve-
locity ratio >2.0). A separate analysis for TASC A and B vs
TASC C and D population is performed.
Results: Between July 2009 and September 2010,
190 patients with TASC A or B and 135 patients with
TASC C or D aortoiliac lesions were included. The demo-
graphic data were comparable for the TASC A/B cohort
and the TASC C/D cohort. Technical success was 100%.
Signiﬁcantly more balloon-expandable stents were
deployed in TASC A and B lesions, and considerably
more self-expanding stents were placed in TASC C and
